Industry Insights: Advanced Breast Cancer Diagnostics
-
By
January 15, 2026
-
11 min
-
1
ESR1 mutations lead to resistance in breast cancer treatment.
-
2
SERDs are a new class of drugs targeting ESR1 mutations.
-
3
ddPCR offers cost-effective testing compared to NGS.
-
4
Accessibility and reimbursement remain critical issues in diagnostics.
-
5
IHC is insufficient for monitoring ESR1 mutations.
-
6
Decentralized testing solutions are vital for low-resource areas.
-
7
Industry partnerships can enhance access to advanced diagnostics.
-
The advancements in breast cancer diagnostics are significantly influenced by the emergence of targeted therapies for ESR1 mutations. These developments compel laboratories to make informed choices about testing platforms that prioritize both efficacy and economic viability. Key figures from Biodesix and Bio-Rad emphasize the challenges of ESR1 testing, including issues of accessibility and reimbursement. The transition from next-generation sequencing (NGS) to more cost-effective solutions like droplet digital PCR (ddPCR) could enhance patient access to suitable treatments, pushing forward the landscape of precision oncology.
-
1
ESR1 mutations lead to resistance in breast cancer treatment.
-
2
SERDs are a new class of drugs targeting ESR1 mutations.
-
3
ddPCR offers cost-effective testing compared to NGS.
-
4
Accessibility and reimbursement remain critical issues in diagnostics.
-
5
IHC is insufficient for monitoring ESR1 mutations.
-
6
Decentralized testing solutions are vital for low-resource areas.
-
7
Industry partnerships can enhance access to advanced diagnostics.
Listen Tab content
